<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Teleflex Incorporated — News on 6ix</title>
<link>https://6ix.com/company/teleflex-incorporated</link>
<description>Latest news and press releases for Teleflex Incorporated on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 10:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/teleflex-incorporated" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c82f78dffbe2df11bc4c.webp</url>
<title>Teleflex Incorporated</title>
<link>https://6ix.com/company/teleflex-incorporated</link>
</image>
<item>
<title>Teleflex Announces First Quarter 2026 Earnings Conference Call Information</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-first-quarter-2026-earnings-conference-call-information</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-first-quarter-2026-earnings-conference-call-information</guid>
<pubDate>Thu, 23 Apr 2026 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., April 23, 2026--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026.</description>
</item>
<item>
<title>Teleflex Announces Governance Updates</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-governance-updates</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-governance-updates</guid>
<pubDate>Thu, 09 Apr 2026 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., April 09, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company’s previously announced program ahead of schedule.</description>
</item>
<item>
<title>Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-2025-financial-results-and-full-year-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-2025-financial-results-and-full-year-2026-outlook</guid>
<pubDate>Thu, 26 Feb 2026 11:30:00 GMT</pubDate>
<description>WAYNE, Pa., February 26, 2026--Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the year ended December 31, 2025.</description>
</item>
<item>
<title>Teleflex Announces Fourth Quarter 2025 Earnings Conference Call Information</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-fourth-quarter-2025-113000969</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-fourth-quarter-2025-113000969</guid>
<pubDate>Tue, 17 Feb 2026 11:30:00 GMT</pubDate>
<description>WAYNE, Pa., February 17, 2026--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026.</description>
</item>
<item>
<title>Teleflex Announces Leadership Transition</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-leadership-transition-113000152</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-leadership-transition-113000152</guid>
<pubDate>Thu, 08 Jan 2026 11:30:00 GMT</pubDate>
<description>Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company’s Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who d</description>
</item>
<item>
<title>Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-sale-acute-care-140400673</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-sale-acute-care-140400673</guid>
<pubDate>Tue, 09 Dec 2025 14:04:00 GMT</pubDate>
<description>Board of Directors authorizes new $1 billion share repurchase programWAYNE, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into definitive agreements to sell the company’s Acute Care, Interventional Urology and OEM businesses to two buyers, Intersurgical® Ltd with respect to Acute Care and Interventional Urology, and Montagu and Kohlberg with respect to OEM, for a combined total of $2.03 b</description>
</item>
<item>
<title>Teleflex to Present at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-present-jefferies-global-healthcare-113000303</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-present-jefferies-global-healthcare-113000303</guid>
<pubDate>Fri, 14 Nov 2025 11:30:00 GMT</pubDate>
<description>WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality</description>
</item>
<item>
<title>Teleflex Announces Quarterly Dividend</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-quarterly-dividend-114500914</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-quarterly-dividend-114500914</guid>
<pubDate>Thu, 06 Nov 2025 11:45:00 GMT</pubDate>
<description>WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2025, to shareholders of record at the close of business on November 14, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through</description>
</item>
<item>
<title>Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-third-quarter-financial-113000375</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-third-quarter-financial-113000375</guid>
<pubDate>Thu, 06 Nov 2025 11:30:00 GMT</pubDate>
<description>WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP revenue of $913.0, up 19.4% compared to the prior year periodAdjusted revenue of $892.9 million, up 16.8% compared to the prior year period, and up 15.3% on an adjusted constant currency basis1GAAP diluted EPS from continuing operations of $(9.24), compared to $2.36 in the prior year</description>
</item>
<item>
<title>Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-third-quarter-2025-203000880</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-third-quarter-2025-203000880</guid>
<pubDate>Thu, 16 Oct 2025 20:30:00 GMT</pubDate>
<description>WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be ava</description>
</item>
<item>
<title>First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients</title>
<link>https://6ix.com/company/teleflex-incorporated/news/first-patient-enrolled-in-dubstent-diabetes-trial-targeting-improved-pci-outcomes-for-diabetic-patients</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/first-patient-enrolled-in-dubstent-diabetes-trial-targeting-improved-pci-outcomes-for-diabetic-patients</guid>
<pubDate>Thu, 11 Sep 2025 10:30:00 GMT</pubDate>
<description>The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting StentsWAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated clinical study will evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. The DUBSTENT DIABE</description>
</item>
<item>
<title>Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-present-morgan-stanley-23rd-103000152</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-present-morgan-stanley-23rd-103000152</guid>
<pubDate>Tue, 26 Aug 2025 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our p</description>
</item>
<item>
<title>Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-launch-barrigel-rectal-103000230</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-launch-barrigel-rectal-103000230</guid>
<pubDate>Tue, 19 Aug 2025 10:30:00 GMT</pubDate>
<description>Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for purchase in Japan, effective immediately following regulatory approval, insurance coverage</description>
</item>
<item>
<title>Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-second-quarter-financial-103000466</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-reports-second-quarter-financial-103000466</guid>
<pubDate>Thu, 31 Jul 2025 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the</description>
</item>
<item>
<title>Teleflex Announces Second Quarter 2025 Earnings Conference Call Information</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-second-quarter-2025-103000014</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-announces-second-quarter-2025-103000014</guid>
<pubDate>Thu, 17 Jul 2025 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be avail</description>
</item>
<item>
<title>Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-completes-acquisition-biotronik-vascular-103000147</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-completes-acquisition-biotronik-vascular-103000147</guid>
<pubDate>Tue, 01 Jul 2025 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business</description>
</item>
<item>
<title>New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients</title>
<link>https://6ix.com/company/teleflex-incorporated/news/prospective-cohort-study-reporting-efficacy-103000546</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/prospective-cohort-study-reporting-efficacy-103000546</guid>
<pubDate>Thu, 12 Jun 2025 10:30:00 GMT</pubDate>
<description>WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified</description>
</item>
<item>
<title>Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-highlights-prostate-health-quality-103000789</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-highlights-prostate-health-quality-103000789</guid>
<pubDate>Wed, 11 Jun 2025 10:30:00 GMT</pubDate>
<description>Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing t</description>
</item>
<item>
<title>Teleflex Publishes 2024 Global Impact Report</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-publishes-2024-global-impact-103000573</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-publishes-2024-global-impact-103000573</guid>
<pubDate>Mon, 19 May 2025 10:30:00 GMT</pubDate>
<description>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility ProgramWAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Account</description>
</item>
<item>
<title>Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting</title>
<link>https://6ix.com/company/teleflex-incorporated/news/teleflex-showcases-clinical-data-presented-103000525</link>
<guid isPermaLink="true">https://6ix.com/company/teleflex-incorporated/news/teleflex-showcases-clinical-data-presented-103000525</guid>
<pubDate>Thu, 15 May 2025 10:30:00 GMT</pubDate>
<description>Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- T</description>
</item>
</channel>
</rss>